Volume 1, Number 1 (Fall 2007)
Volume 1, Number 1 (Fall 2007)
Activity release date: November 19, 2007 • Expiration date: November 19, 2008
This continuing education activity has expired.
Americans are diagnosed with diabetes in greater numbers with each passing year. Fortunately, if detected early, diabetes may be managed successfully with lifestyle changes and, if necessary, drug therapy. This inaugural issue of The Diabetes Report offers insight into the biologic basis of diabetes, the value of genetic studies in identifying factors related to diabetes and in helping to predict whether patients will develop the disease, the chain of events leading to development of diabetic complications, the many factors influencing the development and escalation of diabetes, the devices now available to assist patients in monitoring their blood glucose levels and taking the correct doses of insulin, the results of clinical trials evaluating the safety and efficacy of different drug classes in preventing new-onset diabetes and reducing the risk of diabetic complications, the programs that educate patients about monitoring their blood glucose levels and living a healthier lifestyle, the possibility that women using oral hypoglycemics may be at greater risk of fracture, and the value of combining therapy to attack the disease from different angles. The articles within are based upon presentations delivered during the 67th Scientific Sessions of the American Diabetes Association, held June 22–26, 2007, in Chicago, Illinois.
The articles in this issue, written from the academic perspective of physicians in training at leading medical institutions, summarize the import of these new findings and place them into clinical context. This activity has been developed and approved by a planning committee of nationally recognized thought leaders, under the direction of Beam Institute, to meet a perceived educational need to provide endocrinologists and other physicians who treat diabetes with strategies to help them perform their medical roles.
After reading this issue of The Diabetes Report, participants in this educational activity should be able to:
Endocrinologists and other physicians significantly involved in the diagnosis and management of diabetes should find participating in this educational activity valuable.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Beam Institute and Direct One Communications, Inc. Beam Institute is accredited by the ACCME to provide continuing medical education for physicians.
This program is co-provided by the Boston College William F. Connell School of Nursing Continuing Education Program, Chestnut Hill, Massachusetts. Boston College School of Nursing Continuing Education Program is approved as a provider of continuing education in nursing by the Massachusetts Nurses Association, which is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. This continuing education activity carries 2 contact hours. Participants must read the entire educational activity for contact hours. For further information, contact the Continuing Education program at sonce@bc.edu.
TG Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 2 credit hours (0.2 CEU). Program No. 454-999-07-042-H01-P; initial release date, November 19, 2007; expiration date, November 19, 2010.
In compliance with the ACCME’s Standards for Commercial Support, any person who was in a position to control the content of this CME activity was required to disclose all relevant financial relationships that created conflicts of interest. Beam Institute has identified and resolved all conflicts of interest prior to the publication of this educational activity. All faculty have been offered a modest honorarium for their participation in this activity.
Stephen N. Davis, MD, is Mark Collie Professor of Medicine, Molecular Physiology and Biophysics, and Chair, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee. He has received research grant support from Bayer HealthCare, King Pharmaceuticals, Eli Lilly and Company, Takeda Pharmaceuticals North America, and Sanofi-Aventis.
Jody Dushay, MD, a Clinical Fellow in Endocrinology at Beth Israel Deaconess Medical Center and Joslin Diabetes Center, Boston, Massachusetts, has nothing to disclose.
Ann A. Coulter, PhD, a Postdoctoral Fellow at Pennington Biomedical Research Center, Baton Rouge, Louisiana, has nothing to disclose.
Jennifer M. Perkins, MD, a Clinical Fellow in Diabetes, Metabolism, and Endocrinology at Vanderbilt University School of Medicine, Nashville, Tennessee, is supported by a diabetes/cardiovascular disease fellowship from Takeda Pharmaceuticals North America.
The Beam Institute designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity is an independent educational activity under the direction of Beam Institute. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the American Medical Association, the US Food and Drug Administration, the Office of Inspector General of the US Department of Health and Human Services, and the Pharmaceutical Research and Manufacturers of America Code on Interactions With Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.
However, the planning committee, faculty, Beam Institute, Takeda Pharmaceuticals North America, Inc., and Direct One Communications, Inc. shall in no way be liable for the currency of information or for any errors, omissions, or inaccuracies in this activity. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the planning committee or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants in this activity are encouraged to refer to primary references or full prescribing information resources.
The opinions and recommendations presented herein are those of the faculty and do not necessarily reflect the views of the provider, producer, or grantors.
Copyright owned by Direct One Communications, Inc. © Copyright 2007, Direct One Communications, Inc.
We would like to hear your comments regarding this or other programs provided by the Beam Institute. In addition, suggestions for future programming are welcome. Contact us at:
Director of Continuing Education
Beam Institute
11 West 19th Street, 3rd Floor
New York, NY 10011
Phone: 888-618-5781
Fax: 212-600-3050
E-mail: beaminstitute@cmp.com
The opinions or views expressed in this publication are those of the authors and do not necessarily reflect the opinions or recommendations of Takeda Pharmaceuticals North America, Inc., Beam Institute, or the publisher, Direct One Communications, Inc. Please consult the full prescribing information before using any medication mentioned in this publication.
This program is supported by an educational grant from Takeda Pharmaceuticals North America, Inc.
Copyright © 2007 by Direct One Communications, Inc. All rights reserved.